Antengene Corporation Limited ('Antengene', SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical ...

Patients with spastic paraplegia type 15 develop movement disorders during adolescence that may ultimately require the use of a wheelchair. In the early stages of this rare hereditary disease the ...

Cold' tumors are resistant to common immunotherapies. Researchers have uncovered a master regulator that can be manipulated to prevent tumor growth in mice.

First preclinical data of novel targeted Radio-DARPin against mesothelin (MSLN), in co-development with Orano Med Additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin T cell ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present new data from studies evaluating two of its internally developed, ...

CDR-Life today announced the presentation of data for its novel T cell engager (TCE) programs at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. The presentations ...

CatalYm today announced the presentation of the first preclinical data demonstrating that the company’s clinical-stage ...

Patients with spastic paraplegia type 15 develop movement disorders during adolescence that may ultimately require the use of ...

AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) peptide has garnered attention for its intriguing biological properties ...

Phase 1 trial of TGW101 in advanced solid tumors is enrolling to assess safety and pharmacokinetics and define the maximum ...

How alterations in cell metabolism translate into specific developmental gene programs remains a major question. This study ...